Renaissance Technologies LLC grew its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 84.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,058 shares of the company’s stock after acquiring an additional 9,658 shares during the quarter. Renaissance Technologies LLC owned 0.08% of Oxford Immunotec Global worth $271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Oxford Immunotec Global by 10.0% in the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock worth $16,490,000 after acquiring an additional 116,814 shares during the last quarter. Wasatch Advisors Inc. increased its stake in Oxford Immunotec Global by 18.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 883,761 shares of the company’s stock worth $11,392,000 after acquiring an additional 138,571 shares during the last quarter. Penn Capital Management Co. Inc. increased its stake in Oxford Immunotec Global by 20.4% in the 2nd quarter. Penn Capital Management Co. Inc. now owns 257,026 shares of the company’s stock worth $3,313,000 after acquiring an additional 43,477 shares during the last quarter. C WorldWide Group Holding A S increased its stake in Oxford Immunotec Global by 25.2% in the 2nd quarter. C WorldWide Group Holding A S now owns 164,073 shares of the company’s stock worth $2,115,000 after acquiring an additional 33,059 shares during the last quarter. Finally, Spark Investment Management LLC increased its position in shares of Oxford Immunotec Global by 45.1% during the 2nd quarter. Spark Investment Management LLC now owns 144,100 shares of the company’s stock valued at $1,857,000 after purchasing an additional 44,800 shares during the last quarter. 92.40% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Peter Wrighton-Smith sold 86,100 shares of the business’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the completion of the transaction, the chief executive officer now owns 539,569 shares in the company, valued at approximately $9,938,860.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total value of $46,500.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at approximately $139,500. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,100 shares of company stock worth $2,564,662. Corporate insiders own 6.61% of the company’s stock.
NASDAQ OXFD opened at $15.81 on Friday. The company has a current ratio of 5.39, a quick ratio of 4.86 and a debt-to-equity ratio of 0.41. Oxford Immunotec Global PLC has a fifty-two week low of $10.00 and a fifty-two week high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Friday, November 9th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.14). The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $33.60 million. Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) EPS. As a group, equities research analysts expect that Oxford Immunotec Global PLC will post -0.97 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on OXFD shares. BidaskClub downgraded Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research report on Friday, July 20th. ValuEngine downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. Finally, Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, August 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.67.
TRADEMARK VIOLATION WARNING: “Renaissance Technologies LLC Grows Holdings in Oxford Immunotec Global PLC (OXFD)” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://transcriptdaily.com/2018/11/10/renaissance-technologies-llc-grows-holdings-in-oxford-immunotec-global-plc-oxfd.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Read More: Hedge Funds
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.